Foggetti Giorgia RicercatoreMedicina

RESEARCH ACTIVITY

Curriculum Vitae

Publications

RESEARCH ACTIVITY

 

Lung cancer can be driven by oncogenic alterations in the epidermal growth factor receptor (EGFR) that are found in 15% of cases. The presence of EGFR mutations predicts the response to treatment with specific EGFR inhibitors and these drugs are the approved therapy for patients with this disease. Treatment with EGFR inhibitors improves the survival of patients by blocking the uncontrolled growth and spread of the tumor. However, this therapy does not work in all patients with the same efficacy and resistance to therapy remains a critical challenge, highlighting the need for alternative treatment options.

__

 

Our research interests focus on investigating the biological consequences and the therapeutic significance of tumor suppressor pathway alterations in EGFR mutant lung tumors. We previously found that inactivation of the tumor suppressor KEAP1 is associated with a limited response to therapy. Understanding how dysregulation of the KEAP1 pathway (and additional tumor suppressor pathways) mediates the response and resistance to therapy with EGFR inhibitors could help uncover unique vulnerabilities for specific human tumor subsets that we could potentially target with novel drug combinations. Our overall goal is to contribute to inform precision treatments for patients affected by EGFR-driven lung cancer to improve response to therapy and prevent or overcome drug resistance.

Curriculum Vitae

Education

2012 – 2015                  Ph.D. in Genetics, curriculum: Oncological Genetics and Biology of Differentiation, University of Genoa, Genoa, Italy

2009 – 2011                  Master’s Degree in Cellular and Molecular Biology, University of Genoa, Genoa, Italy. Final grade 110 cum laude and right of publication

2006 – 2009                  Bachelor’s Degree in Cellular and Molecular Biology, University of Genoa, Genoa, Italy. Final grade 110 cum laude

 

Professional experience

Dec 2021 – Present      Principal Investigator, Medical Oncology Department, Vita-Salute San Raffaele University (UniSR), Milan, Italy

Sept 2021 – Present      European Respiratory Society (ERS) Long-Term Research Fellow, Medical Oncology Department, IRCCS Ospedale San Raffaele (OSR), Milan, Italy

Jan 2021 – Jun 2021     Associate Research Scientist, Politi Laboratory, Yale School of Medicine, New Haven, CT, USA

Jul 2016 – Dec 2020     Postdoctoral Associate, Politi Laboratory, Yale School of Medicine, New Haven, CT, USA

Apr 2015 – Jun 2016     Researcher, Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

Jan 2012 – Apr 2015     Ph.D. Student in Genetics, Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

Sep 2009 – Apr 2011    Master’s Student, Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

Jan 2009 – Apr 2009     Undergraduate Student, Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy 

 

Grants

Jan 2022 – Present       Italian Association for Cancer Research (AIRC) Start-Up Grant: “Genomic Mediators of Therapeutic Response in EGFR-Driven Lung Cancer”

Dec 2021 – Present      Lung Cancer Research Foundation (LCRF) – AstraZeneca Research Grant Award: Dissecting the Role of the KEAP1 Pathway in Mediating Therapeutic Sensitivity in EGFR-Driven Lung Adenocarcinoma

Sept 2021 – Aug 2022   ERS Long-Term Research Fellowship (1 year): “Dissecting the Role of the KEAP1 Pathway in Mediating Therapeutic Sensitivity in EGFR-Driven Lung Adenocarcinoma”

Aug 2018 – Jul 2019     American-Italian Cancer Foundation (AICF) Postdoctoral Research Fellowship (2nd year renewal): “Drug Resistance and Metastasis in Lung Adenocarcinoma”

Aug 2017 – Jul 2018     AICF Postdoctoral Research Fellowship (1 year)

Jan 2012 – Dec 2014    Ministry of Education, University, and Research (MIUR) Ph.D. Research Fellowship ‘Human’s health (study and treatment of tumors and degenerative pathologies with new human genome knowledge-derived approaches)’

Publications

  1. Foggetti G#, Li C, Cai H, Petrov DA, Winslow MM, Politi K (2022). Tumor suppressor pathways shape EGFR-driven lung tumor progression and response to treatment. Mol Cell Oncol. PMID: 35252550
  2. Arnal-Estapé A*, Foggetti G*, Starrett JH, Nguyen DX, Politi K (2021). Preclinical models for the study of lung cancer pathogenesis and therapy development. Cold Spring Harb Perspect Med. PMID: 34518338
  3. Foggetti G*, Li C*, Cai H*, Hellyer JA, Lin W, Ayeni D, Hastings K, Choi J, Wurtz A, Andrejka L, Maghini DG, Rashleigh N, Levy S, Homer R, Gettinger S, Diehn M, Wakelee HA, Petrov DA, Winslow MM, Politi K (2021). Genetic determinants of EGFR-driven lung cancer growth and therapeutic response in vivo. Cancer Discov. PMID: 33707235
  4. Monti P, Ciribilli Y, Foggetti G, Menichini P, Bisio A, Cappato S, Inga A, Divizia MT, Lerone M, Bocciardi R, Fronza G (2019). P63 modulates the expression of the WDFY2 gene which is implicated in cancer regulation and limb development. Biosci Rep. PMID: 31789342
  5. Foggetti G, Ottaggio L, Russo D, Mazzitelli C, Monti P, Degan P, Miele M, Fronza G, Menichini P (2019). Autophagy induced by SAHA affects mutant p53 degradation and cancer cell survival. Biosci Rep. PMID: 30745455
  6. Marengo B, Monti P, Miele M, Menichini P, Ottaggio L, Foggetti G, Pulliero A, Izzotti A, Speciale A, Garbarino O, Traverso N, Fronza G and Domenicotti C (2018). Etoposide-resistance in neuroblastoma is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation. Sci Rep. PMID: 30213983
  7. Monti P, Ghiorzo P, Menichini P, Foggetti G, Queirolo P, Izzotti A, Fronza G (2017). TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear. Oncology Reports. PMID: 28849221
  8. Foggetti G, Ottaggio L, Russo D, Monti P, Degan P, Fronza G, Menichini P (2017). Gambogic acid counteracts mutant p53 stability by inducing autophagy. BBA-Molecular Cell Res. PMID: 27899303
  9. Monti P, Foggetti G, Menichini P, Inga A, Gold B, Fronza G (2014). Comparison of the biological effects of MMS and Me-lex, a minor groove methylating agent: Clarifying the role of N3-methyladenine. Mutat Res. PMID: 24211855
  10. Monti P, Ciribilli Y, Bisio A, Foggetti G, Raimondi I, Campomenosi P, Menichini P, Fronza G, Inga A (2014). ∆N-P63α and TA-P63α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites. Oncotarget. PMID: 24926492
  11. Monti P, Russo D, Bocciardi R, Foggetti G, Menichini P, Divizia MT, Lerone M, Graziano C, Wischmeijer A, Viadiu H, Ravazzolo R, Inga A, Fronza G (2013). EEC- and ADULT-Associated TP63 Mutations Exhibit Functional Heterogeneity Towards P63 Responsive Sequences. Hum Mutat. PMID: 23463580
  12. Russo D*, Ottaggio L*, Foggetti G*, Masini M, Masiello P, Fronza G, Menichini P (2013). PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53. BBA-Molecular Cell Res. PMID: 23545415
  13. Ciribilli Y, Monti P, Bisio A, Nguyen HT, Ethayathulla AS, Foggetti G, Menichini P, Menendez D, Resnick MA, Viadiu H, Fronza G, Inga A (2013). Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code. Nucleic Acids Res. PMID: 23892287
  14. Russo D, Ottaggio L, Penna I, Foggetti G, Fronza G, Inga A, Menichini P (2010). PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells. Biochem Biophys Res Commun. PMID: 20946886

*These authors contributed equally to the work

#Corresponding author

Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.